Paysign Q2 revenue up 28% to $11.0M; Adjusted EBITDA $1.1M; guides FY rev $44-46M

Paysign, Inc.

2023-Q2 EPS reported -$0.01 revenue$21,184,341

Revenue $11.0M, up 28% YoY; net loss $0.1M ($0.00 EPS).
Adjusted EBITDA $1.1M, up 23% YoY; FY 2023 guidance revenue $44-46M, Adj EBITDA $6.0-7.5M.
Added 4 net plasma centers, exit at 443; launched 5 new patient affordability programs, now 31 active.
Pharma patient affordability revenue up 133% to $729K; repurchased 119,558 shares for $312K.
Transitioned 16 mature plasma centers in July, total >460 centers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Paysign, Inc. reported the fiscal quarter ended June 30, 2023 results: revenue $11.0 million, net income ($0.1) million, EPS ($0.00) per diluted share.

Period: the fiscal quarter ended June 30, 2023
Revenue: $11.0 million
Net income: ($0.1) million
EPS: ($0.00) per diluted share
Result: reported results

Exact text from the filing

Paysign, Inc. Reports Second Quarter 2023 Financial Results · Second quarter total revenues of $11.0 million, an increase of 28% compared to second quarter 2022 · Second quarter net loss of ($0.1) million and diluted loss per share of ($0.00)

View on SEC.gov

Browse all earnings releases →

Paysign, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-005405

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.